Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | VHL | P40337 | 1/20 | 0.31 |
| ▸ | ELOC | Q15369 | 1/20 | 0.31 |
| ▸ | ELOB | Q15370 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949420 | 1.00 | CHRM2 (0.36) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL16611180 | 0.85 | ALDH1A1 (0.43) | POLBCYP3A4VHLELOCELOB | |
| SCHEMBL16611181 | 0.85 | ALDH1A1 (0.43) | POLBCYP3A4VHLELOCELOB | |
| SCHEMBL15354971 | 0.84 | MMP2 (0.34) | HRH3MAPK1 | |
| SCHEMBL9949884 | 0.83 | CHRM2 (0.38) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL17812928 | 0.83 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL13066371 | 0.83 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL715773 | 0.83 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL1248327 | 0.78 | ATM (0.41) | CYP2C19VHLELOCELOB | |
| SCHEMBL17956421 | 0.78 | ATM (0.41) | CYP2C19VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-9035062-B2 | Process for preparing a compound useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | Meiji Seika Pharma. Co., Ltd. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | Meiji Seika Pharma. Co., Ltd. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8772490-B2 | Optically active diazabicyclooctane derivatives and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8772490-B2 | Optically active diazabicyclooctane derivatives and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2657234-A1 | OPTICALLY-ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR MANUFACTURING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2657234-A1 | OPTICALLY-ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR MANUFACTURING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | DCXR, CBR1, DECR1 | CHRM2 32/4885CHRM1 5/4885CHRM3 89/4885 |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | TBC1D15, TBC1D5, TERT | CHRM2 3870/4885CHRM1 3000/4885CHRM3 3707/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | FN1, FNTB, CPN1 | CHRM2 1270/4885CHRM1 315/4885CHRM3 2504/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CHRM2 634/4885CHRM1 145/4885CHRM3 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.